Holen Sie sich die Stockscreener-App
3.51
3.85%
0.13
Vorhandelsmarkt:
3.45
-0.06
-1.71%
Voyager Therapeutics Inc Aktie (VYGR) Neueste Nachrichten
Voyager Therapeutics stock holds steady as investors watch gene therapy pipeline - AD HOC NEWS
Voyager to Present at Upcoming Investor Conferences - markets.businessinsider.com
Transcript : Voyager Therapeutics, Inc.Special Call - marketscreener.com
Voyager Therapeutics Inc. (VYGR) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Voyager Therapeutics Inc. (VYGR) Peer Comparison – Compare with Others - Value Research
H.C. Wainwright reiterates Voyager Therapeutics stock rating at buy - Investing.com
Voyager Therapeutics (NASDAQ:VYGR) Stock Price Passes Above 50-Day Moving AverageWhat's Next? - MarketBeat
Voyager Therapeutics, Inc.: Financial Data Forecasts Estimates and Expectations | VT6 | US92915B1061 - marketscreener.com
Armistice Capital (VYGR) files 13G/A showing 3.44M Voyager Therapeutics shares - Stock Titan
Voyager to Advance 2 Tau-Targeted Alzheimer Therapies Toward Key Clinical Milestones - NeurologyLive
Voyager’s New Alzheimer’s Trial Puts VYGR on Investors’ Early Watchlist - TipRanks
CCORF Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Analysts Have Just Cut Their Voyager Therapeutics, Inc. (NASDAQ:VYGR) Revenue Estimates By 47% - simplywall.st
HC Wainwright Brokers Raise Earnings Estimates for VYGR - MarketBeat
Voyager Therapeutics (VYGR) Receives a Rating Update from a Top Analyst - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Voyager Therapeutics (VYGR) and Teleflex (TFX) - The Globe and Mail
Voyager Therapeutics (NASDAQ:VYGR) Earns Buy Rating from HC Wainwright - MarketBeat
VYGR Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year - moomoo.com
The Voyager Therapeutics, Inc. (NASDAQ:VYGR) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - simplywall.st
Voyager Therapeutics (VYGR) Stock Rebounds While Cash Runway Concerns Persist - Sahm
Voyager Therapeutics Inc earnings beat by $0.10, revenue fell short of estimates - Investing.com Nigeria
Wedbush Maintains Voyager Therapeutics(VYGR.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Is Voyager Therapeutics Inc (VYGR) Overvalued After Q2 Earnings - GuruFocus
Voyager Therapeutics (NASDAQ:VYGR) Issues Quarterly Earnings Results - MarketBeat
Voyager Therapeutics (VYGR) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
VYGR Looks 86.3% Overvalued on GF Value™ - GuruFocus
Voyager Therapeutics: Q2 Earnings Snapshot - Yahoo Finance
Voyager Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Voyager Reports Second Quarter 2026 Financial and Operating Results - The Manila Times
Voyager Therapeutics reports Q2 2026 net loss $24.5M, cash $148.8M; runway into 2028 - tradingview.com
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows - TradingView
Voyager Therapeutics (Nasdaq: VYGR) gains FDA IND clearance for VY1706 - Stock Titan
VOYAGER THERAPEUTICS Q2 COLLABORATION REVENUE USD 3.165 MILLION - Moomoo
Voyager Therapeutics (VYGR) Edges Higher by 1.45% as Shares Defend $2.99 SupportFibonacci Arc - dars.gov.et
Voyager Therapeutics Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Voyager Therapeutics (VYGR) to Announce Quarterly Earnings on Wednesday - MarketBeat
Voyager Therapeutics Inc (VYGR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
VYGR|Voyager Therapeutics Inc|Price:3.090|Chg%:-0.010 - TradingKey
Voyager Therapeutics Inc (VYGR) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Voyager Therapeutics Inc (VYGR) Valuation: PE, PB & Fair Value Analysis - TradingKey
Voyager Therapeutics Inc (VYGR) Cash Flow - TradingKey
TradingKey - TradingKey
Voyager Therapeutics, Inc. Revenue Breakdown – NASDAQ:VYGR - TradingView
Voyager Therapeutics Inc (VYGR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Voyager Therapeutics Inc. (VYGR) Q1 2026 Earnings: EPS Beat Amid Continued Pre-Clinical FocusEarnings Weakness Phase - dars.gov.et
H.C. Wainwright reiterates Voyager Therapeutics stock rating on tau therapy data - Investing.com Nigeria
Voyager Therapeutics (VYGR) Dips 3.79% as Shares Test Support Near $3.0Exhaustion Gap - dars.gov.et
Voyager Therapeutics Q1 2026 Earnings: Narrower Loss Beats Estimates, Pipeline AdvancesEPS Consistency Score - vinanet.vn
Voyager’s gene therapy reduces tau levels in AD models - BioWorld News
Voyager Therapeutics Drops To US$3.24, Yet Insiders May Have Sold Too Early - Sahm
Voyager Therapeutics advances tau-silencing gene therapy program - tipranks.com
Voyager reports VY1706 Alzheimer’s therapy data - grafa.com
Voyager Therapeutics Presents Positive GLP Toxicology Data for VY1706 Tau Silencing Gene Therapy in Alzheimer’s Disease, Plans Clinical Trial in 2026 – Minichart - Minichart
Voyager Therapeutics (VYGR) Reports Promising VY1706 Data for Al - GuruFocus
Voyager presents six-month data for Alzheimer’s gene therapy By Investing.com - Investing.com Nigeria
[8-K] Voyager Therapeutics, Inc. Reports Material Event - Stock Titan
Voyager presents six-month data for Alzheimer’s gene therapy - Investing.com
Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026 - GlobeNewswire
Voyager Demonstrates Single IV Dose of VY1706 Well - GlobeNewswire
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):